Published in Gene Therapy Weekly, August 26th, 2010
"The year to date is highlighted with a number of significant milestones, culminating with the U.S. launch of OLEPTRO™ earlier this week," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "With OLEPTRO™, we now have two commercial products in the market generating revenue for the Company, both based on our CONTRAMID® technology. As we move forward, we continue to focus on the development and commercialization of differentiated...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.